Omada Health
Omada Health's revenue rose 53.2% to $260 million in fiscal 2025. Its operating margin was −4.6%, up from −25.7% a year earlier. Free cash flow was $17 million. The diluted share count rose 374.5%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
What Omada Health does
Omada Health provides virtual care between doctor visits for people with long-term health conditions. Its members use a mobile app and connected devices such as scales and blood pressure monitors. They get support from health coaches and other care team staff. Its first program, launched in 2012, aims to prevent diabetes and help with weight. It has since added programs for treating diabetes, high blood pressure and high cholesterol, and for people taking GLP-1 weight-loss drugs.
Omada does not charge members. It sells its programs to organizations that pay for health care: employers, health plans, pharmacy benefit managers (companies that run drug coverage for insurers and employers) and health systems. Some customers contract with Omada directly. Others buy through channel partners that resell the programs to their own customers. At the end of 2025 Omada had more than 2,000 customers and over 886,000 members enrolled in one or more programs. It counts a member as enrolled if billed at least once in the past 12 months.
It says it competes through its clinical rigor, its care model that combines people with technology, and the way its single platform covers several conditions. It says its programs are backed by peer-reviewed research and outside accreditations. Omada has a limited operating history and a history of net losses.
Its biggest risks, as it describes them
- A limited operating history, fast growth that may be hard to manage, and a history of net losses.
- Its programs may fail to gain enough market acceptance in a new and changing market.
- Heavy competition, including from companies with more resources and from new technology.
- A large part of sales coming from or through a small number of customers and channel partners.
- Revenue depending on members staying engaged and on its programs showing good health results.
Income statement
Omada Health lost money in fiscal 2025: a net loss of $13 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY23 | FY24 | FY25 |
|---|---|---|---|
| Cash and short-term investments | 116 | 76 | 222 |
| Debt incl. finance leases | — | 30 | 0 |
| Net debt (negative means net cash) | — | −47 | −222 |
| Net debt to EBITDA | — | — | — |
| Debt to equity | — | — | 0.0x |
| Interest coverage | −14.0x | −9.7x | −4.7x |
| Current ratio | — | 2.1x | 3.6x |
| Quick ratio | — | 2.0x | 3.5x |
Cash flow
Projections
Project Omada Health's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What Omada Health says to expect
- Full year 2026: revenue
Revenue in the range of $344 million to $346 million, up from prior guidance of $334 million to $340 million, with the midpoint representing approximately 33% growth compared with 2025.
- Full year 2026: adjusted EBITDA
Adjusted EBITDA in the range of $32 million to $34 million, up from prior guidance of $21 million to $27 million, with the midpoint representing an improvement of approximately $27 million, or roughly five and a half times, compared with 2025.
Insider trades
No officer, director or 10% owner of Omada Health reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY24 | FY25 |
|---|---|---|
| Piotroski F-score | — | — |
| Rule of 40 | 17.8% | 59.8% |
| Altman Z'' | −13.65 | 2.28 |
| Accruals ratio | — | −13.6% |
The nine F-score tests
| Test | FY24 | FY25 |
|---|---|---|
| Net income is positive | — | Fail |
| Cash from operations is positive | Fail | Pass |
| Return on assets rose | — | — |
| Cash from operations exceeds net income | Pass | Pass |
| Debt fell relative to assets | — | — |
| Current ratio rose | — | Pass |
| Share count didn't rise | Fail | Fail |
| Gross margin rose | Pass | Pass |
| Revenue rose relative to assets | — | — |
| F-score | — | — |
Compare
Put Omada Health side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Omada Health | FY25 | 53.2% | −4.6% | 6.5% | — | — | — | |
| HealthStream | FY25 | 4.3% | 6.7% | 19.6% | — | — | — | Compare |
| HeartFlow | FY25 | 39.9% | −36.4% | −33.5% | — | — | — | Compare |
| Certara | FY25 | 8.8% | 5.0% | 22.6% | 0.9% | 1.1x | 5 | Compare |
| Phreesia | FY26 | 14.5% | −1.4% | 14.1% | −2.2% | −2.6x | 6 | Compare |
3 years of figures
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Income statement | |||
| Revenue | 123 | 170 | 260 |
| Revenue growth | — | 38.3% | 53.2% |
| Gross profit | 70 | 103 | 171 |
| Research and development | 34 | 36 | 41 |
| Operating income | −66 | −44 | −12 |
| Net income | −68 | −47 | −13 |
| Diluted EPS (US$) | −9.52 | −6.11 | −0.35 |
| Diluted shares (millions) | 7 | 8 | 37 |
| Cash flow | |||
| Cash from operations | −50 | −34 | 18 |
| Capital expenditure | 0 | 1 | 1 |
| Free cash flow | −50 | −35 | 17 |
| Dividends paid | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 |
| Stock-based compensation | 9 | 9 | 13 |
| Balance sheet at fiscal year end | |||
| Cash and short-term investments | 116 | 76 | 222 |
| Debt incl. finance leases | — | 30 | 0 |
| Total assets | — | 151 | 305 |
| Total liabilities | — | 86 | 76 |
| Shareholders' equity | −350 | −384 | 230 |
| Margins and ratios | |||
| Gross margin | 57.0% | 60.6% | 65.7% |
| Operating margin | −53.8% | −25.7% | −4.6% |
| Net margin | −55.0% | −27.8% | −4.9% |
| Free cash flow margin | −40.9% | −20.5% | 6.5% |
| Rule of 40 (growth + FCF margin) | — | 17.8% | 59.8% |
| Return on capital | — | — | — |
| Return on equity | — | — | — |
| Return on assets | — | — | −5.6% |
| Net debt to EBITDA | — | — | — |